Een onderzoek naar combinatietherapie van amivantamab en carboplatine-pemetrexed, vergeleken met carboplatine-pemetrexed, bij deelnemers met gevorderde of gemetastaseerde niet-kleincellige longkanker gekenmerkt door epidermale groeifactorreceptor (EGFR) Exon 20-inserties (PAPILLON)
61186372NSC3001: A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in combination with chemotherapy, versus chemotherapy alone in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by EGFR Exon 20ins mutations.
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Studietype
Studietype
Inschrijving (Werkelijk)
Inschrijving
Fase
Fase
- Fase 3
Uitgebreide toegang
Uitgebreide toegang
Goedgekeurd
- Beschikbaar: Uitgebreide toegang is momenteel beschikbaar voor deze onderzoeksbehandeling, en patiënten die niet deelnemen aan de klinische studie kunnen mogelijk toegang krijgen tot het geneesmiddel, biologische of medische hulpmiddel wordt onderzocht.
- Niet langer beschikbaar: Uitgebreide toegang was eerder beschikbaar voor deze interventie, maar is momenteel niet beschikbaar en zal in de toekomst niet beschikbaar zijn.
- Tijdelijk niet beschikbaar: Uitgebreide toegang is momenteel niet beschikbaar voor deze interventie, maar zal naar verwachting in de toekomst beschikbaar zijn.
- Goedgekeurd voor marketing: De interventie is goedgekeurd door de Amerikaanse Food and Drug Administration voor gebruik door het publiek.
Contacten en locaties
Studie Locaties
-
-
-
Camperdown, Australië, 2050
- Chris O'Brien Lifehouse
-
Kogarah, Australië, 2217
- St George Hospital
-
Malvern, Australië, 3144
- Cabrini Medical Centre
-
Nedlands, Australië, 6009
- Sir Charles Gairdner Hospital
-
-
-
-
-
Leuven, België, 3000
- UZ Leuven
-
Roeselare, België, 8800
- Algemeen Ziekenhuis Delta
-
Yvoir, België, 5530
- CHU UCL Namur - Site Godinne
-
-
-
-
-
Barretos, Brazilië, 14784-400
- Fundacao Pio XII
-
Belo Horizonte, Brazilië, 30110-017
- Cetus Oncologia
-
Florianópolis, Brazilië, 88020-210
- Ynova Pesquisa Clinica
-
Ijuí, Brazilië, 98700-000
- Oncosite - Centro de Pesquisa Clínica em Oncologia Ltda
-
Natal, Brazilië, 59062 000
- Liga Norte Riograndense Contra O Cancer
-
Pelotas, Brazilië, 96020 080
- UPCO Unidade de Pesquisa Clinica em Oncologia
-
Porto Alegre, Brazilië, 90020-090
- Irmandade Santa Casa de Misericordia de Porto Alegre
-
Porto Alegre, Brazilië, 90610-000
- Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS
-
Rio de Janeiro, Brazilië, 22 250 905
- Oncoclinicas Rio de Janeiro S A
-
Rio de Janeiro, Brazilië, 22281 100
- Instituto D Or de Pesquisa e Ensino IDOR
-
Rio de Janeiro, Brazilië, 20231 050
- Ministerio da Saude Instituto Nacional do Cancer
-
Sorocaba, Brazilië, 18030-075
- IOS - Instituto de Oncologia de Sorocaba Dr. Gilson Delgado
-
São Paulo, Brazilië, 04014-002
- Núcleo de Pesquisa São Camilo
-
São Paulo, Brazilië, 01509 900
- Fundacao Antonio Prudente A C Camargo Cancer Center
-
São Paulo, Brazilië, 01246 000
- Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo
-
Vitória, Brazilië, 29308-014
- Hospital Evangélico de Cachoeiro de Itapemirim
-
-
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 8L6
- The Ottawa Hospital Cancer Centre
-
Toronto, Ontario, Canada, M4N 3M5
- Sunnybrook Health Sciences Centre
-
-
Quebec
-
Montreal, Quebec, Canada, H4A 3J1
- McGill University Health Centre
-
-
-
-
-
Beijing, China, 100142
- Beijing Cancer Hospital
-
Beijing, China, 100853
- Chinese PLA General Hospital
-
Beijing, China, 102206
- Peking University International Hospital
-
Beijing, China, 100142
- Beijing Cancer Hospital Chest Tumor Internal Medicine dept. II
-
Beijing, China, 101199
- Beijing Chest hospital, Capital medical university
-
Changchun, China, 130000
- Jilin cancer hospital
-
Changsha, China, 410013
- Hunan Cancer Hospital Chest Tumor Internal Medicine dept. II
-
Changsha, China, 410013
- Hunan Cancer hospital
-
Changzhou, China, 213003
- The First People's Hospital Of Changzhou
-
Chengdu, China, 610041
- West China Hospital Sichuan University
-
Chongqing, China, 400030
- Chongqing University Cancer Hospital
-
Fuzhou, China, 350001
- Fujian Medical University Union Hospital
-
Guangzhou, China, 510080
- The First Affiliated Hospital Sun Yat sen University
-
Hangzhou, China, 310022
- Zhejiang Cancer Hospital
-
Hangzhou, China, 310009
- The Second Affiliated Hospital of Zhejiang University College of Medicine
-
Hangzhou, China, 310003
- The First Affiliated Hospital Zhejiang University College of Medicine
-
Hangzhou, China, 310016
- Sir Run Run Shaw Hospital Zhejiang University School of Medicine
-
Hangzhou, China, 310009
- The Second Affiliated Hospital of Zhejiang University College of Medicine 1
-
Harbin, China, 150000
- Harbin medical university cancer hospital
-
Linhai, China, 317000
- Taizhou Hospital of Zhejiang Province
-
Nanjing, China, 210031
- Nanjing Drum Tower Hospital
-
Shanghai, China, 200030
- Shanghai Chest Hospital
-
Shanghai, China, 200032
- Fudan University Shanghai Cancer Center
-
Shanghai, China, 200433
- Shanghai Pulmonary Hospital
-
Shanghai, China, 200123
- Shanghai East Hospital
-
Shenyang, China, 110004
- Shengjing Hospital Of China Medical University
-
Shenzhen, China, 518116
- Cancer hospital Chinese Academy of Medical Sciences, Shenzhen Center
-
Tianjin, China, 300052
- Tianjin Medical University General Hospital
-
Weifang, China, 261000
- Weifang People's Hospital
-
Wuhan, China, 430030
- TongJi Hospital of TongJi Medical College of Huazhong University of Science & Technology
-
Wuxi, China, 214122
- Hospital of Jiangnan University
-
Xi'an, China, 710061
- The First Affiliated Hospital of Xian Jiaotong University
-
Yantai, China, 264000
- Yantai Yuhuangding Hospital
-
Zhengzhou, China, 450008
- Henan Cancer Hospital
-
-
-
-
-
Bad Berka, Duitsland, 99437
- Zentralklinik Bad Berka GmbH
-
Berlin, Duitsland, 13125
- Evangelische Lungenklinik Berlin
-
Cologne, Duitsland, 50937
- Universitaetsklinikum Koeln
-
Cologne, Duitsland, 51109
- Kliniken der Stadt Koeln gGmbH
-
Gauting, Duitsland, 82131
- Asklepios Klinik Gauting GmbH - Asklepios Fachkliniken Munchen-Gauting
-
Heidelberg, Duitsland, 69126
- Thoraxklinik am Universitatsklinikum Heidelberg
-
Heilbronn, Duitsland, 74072
- Onkologische Schwerpunktpraxis
-
Moers, Duitsland, 47441
- Bethanien Krankenhaus
-
Oldenburg, Duitsland, 26121
- Pius-Hospital Oldenburg
-
Recklinghausen, Duitsland, 45659
- Oncologianova GmbH
-
-
-
-
-
Bordeaux, Frankrijk, 33000
- Institut Bergonie
-
Bron, Frankrijk, 69500
- Hospices Civils de Lyon HCL
-
Dijon, Frankrijk, 21000
- Centre Georges Francois Leclerc
-
Le Mans, Frankrijk, 72037
- Centre Hospitalier Le Mans
-
Lille, Frankrijk, 59037
- CHR Hôpital Calmette
-
Nantes, Frankrijk, 44093
- CHU Nantes - Hopital Nord Laënnec
-
Paris, Frankrijk, 75005
- Institut Curie
-
Pessac, Frankrijk, 33604
- CHU Bordeaux
-
Saint-Mandé, Frankrijk, 94163
- HIA Begin
-
-
-
-
-
Budapest, Hongarije, H-1529
- Orszagos Koranyi Tbc es Pulmonologiai Intezet
-
Gyöngyös, Hongarije, 3233
- Mátrai Gyógyintézet-Bronchológia
-
Szombathely, Hongarije, 9700
- Markusovszky Egyetemi Oktatokorhaz
-
Székesfehérvár, Hongarije, 8000
- Fejer Varmegyei Szent Gyorgy Egyetemi Oktatokorhaz
-
Törökbálint, Hongarije, 2045
- Tudogyogyintezet Torokbalint
-
-
-
-
-
Hyderabad, Indië, 500034
- Basavatarakam Indo-American Hospital
-
Kolkata, Indië, 700160
- Tata Medical Center
-
Mumbai, Indië, 400012
- Tata Memorial Hospital
-
Nashik, Indië, 422002
- HCG Manavta Cancer Centre
-
New Delhi, Indië, 110085
- Rajiv Gandhi Cancer Institute & Research Centre
-
Pune, Indië, 411013
- Noble Hospital Pvt Ltd
-
-
-
-
-
Jerusalem, Israël, 91031
- Shaare Zedek Medical Center
-
Jerusalem, Israël, 9112001
- Hadassah Medical Center
-
Kfar Saba, Israël, 44281
- Meir Medical Center
-
Petah Tikva, Israël, 49100
- Rabin Medical Center
-
Tel Aviv, Israël, 6423906
- Tel Aviv Sourasky Medical Center
-
-
-
-
-
Bologna, Italië, 40138
- A O U Sant Orsola Malpighi
-
Catania, Italië, 95123
- Azienda Ospedaliero Univ. Policlinico Gaspare Rodolico
-
Meldola, Italië, 47014
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
-
Milan, Italië, 20132
- IRCCS Ospedale San Raffaele
-
Milan, Italië, 20133
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Milan, Italië, 20122
- Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
-
Monza, Italië, 20052
- San Gerardo Hospital
-
Ravenna, Italië, 48121
- Ospedale S. Maria Delle Croci
-
Roma, Italië, 00168
- Irccs Gemelli
-
Rozzano, Italië, 20089
- Istituto Clinico Humanitas
-
-
-
-
-
Bunkyō City, Japan, 113 8431
- Juntendo University Hospital
-
Hidaka, Japan, 350-1298
- Saitama Medical University International Medical Center
-
Himeji, Japan, 670-8520
- National Hospital Organization Himeji Medical Center
-
Hirakata, Japan, 573 1191
- Kansai Medical University Hospital
-
Kanazawa, Japan, 920 8641
- Kanazawa University Hospital
-
Kashiwa, Japan, 277 8577
- National Cancer Center Hospital East
-
Kishiwada, Japan, 596-8501
- Kishiwada City Hospital
-
Kobe, Japan, 650-0047
- Kobe City Medical Center General Hospital
-
Kurashiki, Japan, 710-8602
- Kurashiki Central Hospital
-
Kurume, Japan, 830-0011
- Kurume University Hospital
-
Matsusaka, Japan, 515-8544
- Matsusaka Municipal Hospital
-
Nagoya, Japan, 460-0001
- National Hospital Organization Nagoya Medical Center
-
Nagoya, Japan, 464 8681
- Aichi Cancer Center Hospital
-
Niigata, Japan, 951-8566
- Niigata Cancer Center Hospital
-
Osaka Sayama Shi, Japan, 589 8511
- Kindai University Hospital
-
Sagamihara, Japan, 252-0375
- Kitasato University Hospital
-
Sapporo, Japan, 060-8648
- Hokkaido University Hospital
-
Shiwa-gun, Japan, 028-3695
- Iwate Medical University Hospital
-
Shizuoka, Japan, 411 8777
- Shizuoka Cancer Center
-
Tokyo, Japan, 135 8550
- The Cancer Institute Hospital of JFCR
-
Toon-shi, Japan, 791-0295
- Ehime University Hospital
-
Wakayama, Japan, 641 8510
- Wakayama Medical University Hospital
-
Yamaguchi, Japan, 755-0241
- National Hospital Organization Yamaguchi Ube Medical Center
-
-
-
-
-
George Town, Maleisië, 10990
- Hospital Pulau Pinang
-
Johor Bahru, Maleisië, 81100
- Hospital Sultan Ismail
-
Kuala Lumpur, Maleisië, 50586
- Hospital Kuala Lumpur
-
Kuala Lumpur, Maleisië, 59100
- University Malaya Medical Centre
-
-
-
-
-
Chihuahua City, Mexico, 31217
- Centro Oncologico de Chihuahua
-
Guadalajara, Mexico, 44280
- Hospital Civil de Guadalajara Fray Antonio Alcalde
-
Mexico City, Mexico, 14080
- Instituto Nacional de Cancerologia
-
Mexico City, Mexico, 14050
- Médica Sur
-
Mexico City, Mexico, 03100
- Mexico Centre for Clinical Research, S.A. de C.V.
-
Monterrey, Mexico, 64710
- i Can Oncology Center
-
México, Mexico, 03100
- Health Pharma Professional Research
-
Naucalpan, Mexico, 53100
- Oncologia Integral Satelite
-
-
-
-
-
Dnipro, Oekraïne, 49102
- Dnipropetrovsk State Medical Academy, Dnipropetrovsk City Multifield Clinical Hospital # 4
-
Kyiv, Oekraïne, 02091
- Medical Center 'Ok Clinic' of LLC 'International Institute of Clinical Studies'
-
Kyiv, Oekraïne, 03022
- National Cancer Institute
-
-
-
-
-
Bydgoszcz, Polen, 85 796
- Centrum Onkologii im Prof F Lukaszczyka
-
Gdansk, Polen, 80 214
- Uniwersyteckie Centrum Kliniczne
-
Gdynia, Polen, 81 519
- Szpitale Pomorskie Sp z o o
-
Olsztyn, Polen, 10-357
- Warminsko-Mazurskie Centrum Chorob Pluc w Olsztynie
-
Poznan, Polen, 60-693
- Private Specialist Hospitals - MedPolonia
-
Warsaw, Polen, 02-781
- Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
-
-
-
-
-
Lisbon, Portugal, G1R 2J6
- Uls Sao Jose - Hosp. Sto Antonio Dos Capuchos
-
Lisbon, Portugal, 1998-018
- Hosp. Cuf Descobertas
-
Porto, Portugal, 4200-072
- Instituto Portugues de Oncologia
-
Porto, Portugal, 4099-001
- Centro Hospitalar Universitario do Porto, EPE
-
Vila Nova de Gaia, Portugal, 4434 502
- Centro Hospitalar de Vila Nova de Gaia Espinho E P E
-
-
-
-
-
Rio Piedras, Puerto Rico, 00935
- Pan American Center for Oncology Trials LLC
-
-
-
-
-
Irkutsk, Rusland, 664035
- Irkutsk Regional Oncology Dispensary
-
Krasnogorsk, Rusland, 143423
- Moscow City Oncology Hospital No 62
-
Krasnoyarsk, Rusland, 660133
- Krasnoyarsk Regional Oncology Dispensary
-
Kuzmolovsky, Rusland, 188663
- Leningrad Regional Oncology Dispensary
-
Moscow, Rusland, 115533
- MCK
-
Nal'chik, Rusland, 360000
- City Clinical Hospital #1
-
Nizhny Novgorod, Rusland, 603000
- Nizhny Novgorod Regional Oncological Dispensary
-
Saint Petersburg, Rusland, 197758
- N.N. Petrov Research Institute Of Oncology
-
Saint Petersburg, Rusland, 194291
- Leningrad Regional Clinical Hospital
-
Saint Petersburg, Rusland, 196006
- Oncology Medical Clinics AV Medical group
-
Tomsk, Rusland, 634050
- Tomsk Cancer Research Institute
-
Ufa, Rusland, 450083
- Bashkir State Medical University
-
Yaroslavl, Rusland, 150054
- Yaroslavl Regional Clinical Oncology Hospital
-
-
-
-
-
A Coruña, Spanje, 15006
- Hosp Univ A Coruna
-
Badalona, Spanje, 08916
- Inst. Cat. D'Oncologia-Badalona
-
Barcelona, Spanje, 08025
- Hosp. de La Santa Creu I Sant Pau
-
Barcelona, Spanje, 08028
- Hosp. Univ. Quiron Dexeus
-
Barcelona, Spanje, 08035
- Hosp Univ Vall D Hebron
-
Burgos, Spanje, 09003
- Hosp. Univ. de Burgos
-
Madrid, Spanje, 28041
- Hosp. Univ. 12 de Octubre
-
Madrid, Spanje, 28034
- Hosp. Univ. Ramon Y Cajal
-
Madrid, Spanje, 28046
- Hosp. Univ. La Paz
-
Madrid, Spanje, 28007
- Hosp. Gral. Univ. Gregorio Maranon
-
Majadahonda, Spanje, 28222
- Hosp. Univ. Pta. de Hierro Majadahonda
-
Málaga, Spanje, 29010
- Hosp Virgen de La Victoria
-
Pamplona, Spanje, 31008
- Clinica Univ. de Navarra
-
Seville, Spanje, 41013
- Hosp. Virgen Del Rocio
-
Zaragoza, Spanje, 50009
- Hosp. Clinico Univ. Lozano Blesa
-
-
-
-
-
Kaohsiung City, Taiwan, 807
- Kaohsiung Medical University Chung Ho Memorial Hospital
-
Kaohsiung City, Taiwan, 833
- Chang Gung Medical Foundation
-
New Taipei City, Taiwan, 23561
- Taipei Medical University Shuang Ho Hospital
-
Taichung, Taiwan, 40447
- China Medical University Hospital
-
Taichung, Taiwan, 402
- Chung Shan Medical University Hospital
-
Taipei, Taiwan, 10002
- National Taiwan University Hospital
-
-
-
-
-
Bangkok, Thailand, 10700
- Siriraj Hospital
-
Bangkok, Thailand, 10400
- Phramongkutklao Hospital and Medical College
-
Songkhla, Thailand, 90110
- Songklanagarind Hospital, Prince of Songkla University
-
-
-
-
-
Adana, Turkije (Türkiye), 01060
- Adana City Hospital
-
Adana, Turkije (Türkiye), 01250
- Başkent University Medical Faculty Adana Application and Research Center
-
Ankara, Turkije (Türkiye), 6560
- Gazi University Hospital
-
Ankara, Turkije (Türkiye), 6800
- Ankara Bilkent City Hospital
-
Edirne, Turkije (Türkiye), 22030
- Trakya University Medical Faculty
-
Istanbul, Turkije (Türkiye), 34722
- Goztepe Prof Dr Suleyman Yalcin Sehir Hastanesi
-
Istanbul, Turkije (Türkiye), 34098
- Istanbul Universitesi Cerrahpasa Tip Fakultesi Ic Hastaliklari Anabilim Dali Medikal Onkoloji Bd
-
Istanbul, Turkije (Türkiye), 34214
- Medipol Mega University Hospital
-
Izmir, Turkije (Türkiye), 35580
- Izmir Medical Park Hospital
-
-
-
-
-
Edinburgh, Verenigd Koninkrijk, EH4 2XU
- Edinburgh Cancer Centre Western General
-
London, Verenigd Koninkrijk, SW3 6JJ
- The Royal Marsden NHS Trust Chelsea
-
Sutton, Verenigd Koninkrijk, SM2 5PT
- The Royal Marsden NHS Trust Sutton
-
-
-
-
California
-
Duarte, California, Verenigde Staten, 91010
- City of Hope 2
-
Orange, California, Verenigde Staten, 92868
- University of California Irvine
-
Santa Monica, California, Verenigde Staten, 90404
- UCLA
-
-
District of Columbia
-
Washington D.C., District of Columbia, Verenigde Staten, 20007
- Georgetown University Hospital
-
-
Florida
-
Tampa, Florida, Verenigde Staten, 33612
- H. Lee Moffitt Cancer & Research Institute
-
-
Georgia
-
Athens, Georgia, Verenigde Staten, 30607
- University Cancer And Blood Center LLC
-
-
Michigan
-
Detroit, Michigan, Verenigde Staten, 48202
- Henry Ford Hospital
-
-
Missouri
-
St Louis, Missouri, Verenigde Staten, 63110
- Washington University Medical Center
-
-
New Jersey
-
East Brunswick, New Jersey, Verenigde Staten, 08816
- Regional Cancer Care Associates LLC
-
-
New York
-
New York, New York, Verenigde Staten, 10032
- Columbia University Medical Center
-
New York, New York, Verenigde Staten, 10016
- Langone Health at NYC University, NYU School of Medicine
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97213
- Providence Portland Medical Center
-
-
South Dakota
-
Sioux Falls, South Dakota, Verenigde Staten, 57104
- Sanford Health
-
-
Texas
-
Tyler, Texas, Verenigde Staten, 75702
- Texas Oncology Pa
-
-
Utah
-
Salt Lake City, Utah, Verenigde Staten, 84106
- Utah Cancer Specialists
-
-
Virginia
-
Fairfax, Virginia, Verenigde Staten, 22031
- Virginia Cancer Specialists
-
Salem, Virginia, Verenigde Staten, 24153
- Blue Ridge Cancer Care
-
-
-
-
-
Busan, Zuid -Korea, 48108
- Inje University Haeundae Paik Hospital
-
Gyeonggi-do, Zuid -Korea, 10408
- National Cancer Center 1
-
Gyeongsangnam-do, Zuid -Korea, 52727
- GyeongSang National University Hospital
-
Jeollanam-do, Zuid -Korea, 58128
- Chonnam National University Hwasun Hospital
-
Seongnam-si, Zuid -Korea, 13620
- Seoul National University Bundang Hospital
-
Seoul, Zuid -Korea, 05505
- Asan Medical Center
-
Seoul, Zuid -Korea, 03722
- Severance Hospital Yonsei University Health System
-
Seoul, Zuid -Korea, 06351
- Samsung Medical Center
-
Seoul, Zuid -Korea, 03181
- Kangbuk Samsung Hospital
-
Seoul, Zuid -Korea, 02841
- Korea University Anam Hospital
-
Seoul, Zuid -Korea, 06591
- The Catholic University of Korea Seoul St Mary s Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Participant must have histologically or cytologically confirmed, locally advanced or metastatic, nonsquamous non-small cell lung cancer (NSCLC) with documented primary epidermal growth factor receptor (EGFR) Exon 20ins activating mutation
- Participant must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
- Participant must have Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Participant must agree to genetic characterization of tumor status through the required pretreatment tumor biopsy (or submission of equivalent archival material), as well as baseline and periodic blood samples for analysis of tumor mutations in the bloodstream
- A female participant of childbearing potential must have a negative serum or urine test at screening and within 72 hours of the first dose of study treatment and must agree to further serum or urine pregnancy tests during the study
Exclusion Criteria:
- Participant has evidence of synchronous NSCLC disease (as suggested by genetic characterization or radiographic appearance)
- Participant has untreated brain metastases (a participant with definitively, locally treated metastases who is clinically stable, asymptomatic, and off corticosteroid treatment for at least 2 weeks prior to randomization is eligible)
- Participant has history of spinal cord compression that has not been treated definitively with surgery or radiation
- Participant has a medical history of interstitial lung disease (ILD), including drug-induced ILD, or radiation pneumonitis
- Participant has a contraindication to the use of carboplatin or pemetrexed (refer to local prescribing information for each agent). Participant has a history of hypersensitivity to, or cannot take, vitamin B12 or folic acid
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: Arm A: Amivantamab + Chemotherapy
Participants will receive pemetrexed 500 milligram per meter square (mg/m^2) intravenous (IV) infusion (with vitamin supplementation) on Day 1 of each 21-day cycle, in combination with carboplatin for up to 4 cycles, and then as maintenance monotherapy until disease progression. Carboplatin area under the concentration-time curve 5 milligram per milliliter (mg/mL) per minute (AUC 5) will be administered as IV infusion on Day 1 of each 21 day cycle, for up to 4 cycles. Participants will receive amivantamab 1400 mg (1750 mg if body weight is >=80 kilogram [kg]) by IV infusion once weekly up to Cycle 2 Day 1, then 1750 mg (2100 mg if body weight is >=80 kg) on Day 1 of each 21-day cycle, starting with Cycle 3. Following the primary analysis for efficacy, the study will transition to an OLE phase and participants will continue to receive the amivantamab plus chemotherapy in OLE phase. Participants who completed OLE period will enter LTE period and continue to receive same treatment. |
Amivantamab will be administered as an IV infusion at a dose of 1400 mg (1750 mg if body weight is >=80 kilogram [kg]) by once weekly up to Cycle 2 Day 1, then 1750 mg (2100 mg if body weight is >=80 kg) on Day 1 of each 21-day cycle, starting with Cycle 3 and will continue the same treatment in OLE phase then in LTE phase.
Andere namen:
Pemetrexed will be administered as 500 mg/m^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm A and will continue the same treatment in OLE phase then in LTE phase. Carboplatin will be administered as AUC 5 IV infusion for up to 4 cycles on Day 1 of each 21-day cycle. Pemetrexed will be administered as 500 mg/m^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm B and will continue the same treatment in OLE phase then in LTE phase. |
|
Experimenteel: Arm B: Chemotherapy Alone
Participants will receive pemetrexed 500 mg/m^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle, in combination with carboplatin for up to 4 cycles, and then as maintenance monotherapy until disease progression. Carboplatin AUC 5 IV infusion will be administered on Day 1 of each 21-day cycle for up to 4 cycles. Following the primary analysis for efficacy, the study will transition to an OLE phase and participants will either continue to receive the chemotherapy or cross over to amivantamab in OLE phase. Participants who completed OLE period will enter LTE period and continue to receive same treatment. |
Pemetrexed will be administered as 500 mg/m^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm A and will continue the same treatment in OLE phase then in LTE phase. Carboplatin will be administered as AUC 5 IV infusion for up to 4 cycles on Day 1 of each 21-day cycle. Pemetrexed will be administered as 500 mg/m^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm B and will continue the same treatment in OLE phase then in LTE phase. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)
Tijdsspanne: From randomization to either disease progression or death whichever occurs first (up to 29 months)
|
PFS was defined as the time from randomization until the date of objective disease progression based on BICR using RECIST version 1.1 or death (by any cause) in the absence of progression, whichever came first. Participants who have not progressed or have not died at the time of analysis were censored at the time of the latest date of their last evaluable RECIST version 1.1 assessment. Pharmacodynamic: Sum of diameters increased by greater than or equal to (>=)20 percent (%) and >=5 millimeter (mm) from nadir (including baseline if it was smallest sum). |
From randomization to either disease progression or death whichever occurs first (up to 29 months)
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Objectief responspercentage (ORR)
Tijdsspanne: Tot 5 jaar en 3 maanden
|
Tot 5 jaar en 3 maanden
|
|
Duur van de respons (DoR)
Tijdsspanne: Tot 5 jaar en 3 maanden
|
Tot 5 jaar en 3 maanden
|
|
Algemene overleving (OS)
Tijdsspanne: Tot 5 jaar en 3 maanden
|
Tot 5 jaar en 3 maanden
|
|
Tijd tot daaropvolgende therapie (TST)
Tijdsspanne: Tot 5 jaar en 3 maanden
|
Tot 5 jaar en 3 maanden
|
|
Progressievrije overleving na eerste daaropvolgende therapie (PFS2)
Tijdsspanne: Tot 5 jaar en 3 maanden
|
Tot 5 jaar en 3 maanden
|
|
Tijd tot symptomatische progressie (TTSP)
Tijdsspanne: Tot 5 jaar en 3 maanden
|
Tot 5 jaar en 3 maanden
|
|
Aantal deelnemers Behandelingsgerelateerde bijwerkingen (TEAE’s)
Tijdsspanne: Van dag 1 tot 5 jaar en 2 maanden
|
Van dag 1 tot 5 jaar en 2 maanden
|
|
Aantal deelnemers TEAE's met ernst
Tijdsspanne: Van dag 1 tot 5 jaar en 2 maanden
|
Van dag 1 tot 5 jaar en 2 maanden
|
|
Aantal deelnemers met klinische laboratoriumafwijkingen
Tijdsspanne: Tot 5 jaar en 3 maanden
|
Tot 5 jaar en 3 maanden
|
|
Aantal deelnemers met afwijkingen in de vitale functies
Tijdsspanne: Tot 5 jaar en 3 maanden
|
Tot 5 jaar en 3 maanden
|
|
Aantal deelnemers met afwijkingen bij lichamelijk onderzoek
Tijdsspanne: Tot 5 jaar en 3 maanden
|
Tot 5 jaar en 3 maanden
|
|
Serumconcentratie van Amivantamab
Tijdsspanne: Dag 1 (cycli 1, 2, 3, 5, 7, 9, 11, 13), dag 2 (cyclus 1)
|
Dag 1 (cycli 1, 2, 3, 5, 7, 9, 11, 13), dag 2 (cyclus 1)
|
|
Aantal deelnemers met anti-amivantamab-antilichamen
Tijdsspanne: Dag 1 (cycli 1, 2, 3, 5, 7, 9, 11, 13), dag 2 (cyclus 1)
|
Dag 1 (cycli 1, 2, 3, 5, 7, 9, 11, 13), dag 2 (cyclus 1)
|
|
Verandering ten opzichte van de uitgangssituatie in de Europese organisatie voor onderzoek en behandeling van kanker Vragenlijst over de kwaliteit van leven Core 30 (EORTC-QLQ-C30)
Tijdsspanne: Vanaf baseline tot 5 jaar en 3 maanden
|
Vanaf baseline tot 5 jaar en 3 maanden
|
|
Verandering ten opzichte van de uitgangswaarde in door de patiënt gerapporteerde resultaten Meetinformatiesysteem-fysieke functie (PROMIS-PF)
Tijdsspanne: Vanaf baseline tot 5 jaar en 3 maanden
|
Vanaf baseline tot 5 jaar en 3 maanden
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Onderzoekers
Onderzoekers
- Studie directeur: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Publicaties en nuttige links
Algemene publicaties
- Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares L, Cheng S, Kitazono S, Thiagarajan M, Goldman JW, Sabari JK, Sanborn RE, Mansfield AS, Hung JY, Boyer M, Popat S, Mourao Dias J, Felip E, Majem M, Gumus M, Kim SW, Ono A, Xie J, Bhattacharya A, Agrawal T, Shreeve SM, Knoblauch RE, Park K, Girard N; PAPILLON Investigators. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023 Nov 30;389(22):2039-2051. doi: 10.1056/NEJMoa2306441. Epub 2023 Oct 21.
- Sanborn RE, Zhou C, Tang KJ, Cho BC, Cheng S, Popat S, Ono A, Lu S, Majem M, Aguilar A, Del Rosario Garcia Campelo M, Hayashi H, Lee KY, Lee SH, Delmonte A, Alatorre-Alexander J, Richardson G, Santos V, Dooms C, Sabari JK, Shu CA, Girard N, Mansfield AS, Park K, Xia Y, Bhattacharya A, Buyukkaramikli N, Perualila N, Diels J, Acharya S, Chandler C, Proskorovsky I, Dearden L, Wortman-Vayn H, Mahadevia PJ, Knoblauch RE, Agrawal T, Baig M, Felip E. Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study. Target Oncol. 2025 Nov;20(6):979-989. doi: 10.1007/s11523-025-01182-0. Epub 2025 Nov 3.
- Kitazono S, Ono A, Kawamura T, Hataji O, Tanaka H, Matsumoto S, Watanabe N, Nagashima H, Oki M, Takahashi M, Anazawa T, Shirai T, Yamashita A, Wortman-Vayn H, Bhattacharya A, Agrawal T, Baig M, Knoblauch RE, Hayashi H. Amivantamab Plus Chemotherapy in Japanese Patients With EGFR Exon 20 Insertions NSCLC. Cancer Sci. 2025 Nov;116(11):3139-3148. doi: 10.1111/cas.70180. Epub 2025 Sep 8.
- Zhou C, Tang KJ, Liu B, Kim SW, Kitazono S, Ono A, Thiagarajan M, Hung JY, Boyer M, CIl T, Yao Y, Nagarkar R, Xie J, Bhattacharya A, Wortman-Vayn H, Baig M, Agrawal T, Lorenzini P, Lee SH, Cho BC. Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis. Lung Cancer. 2026 Mar;213:109302. doi: 10.1016/j.lungcan.2026.109302. Epub 2026 Feb 2.
- Tang K, Wu F, Yang F, Yao Y, Zhao Y, Zhou J, Sun P, Wang D, Lv D, Wang H, Hu Y, Li Q, Song Y, Gao G, Pan F, Bhattacharya A, Baig M, Lorenzini PA, Wortman-Vayn H, Agrawal T, Zhou C. Amivantamab plus chemotherapy vs. chemotherapy as first-line treatment in Chinese mainland patients with EGFR exon 20 insertion non-small cell lung cancer: Subgroup analysis of the randomized PAPILLON trial. Chin Med J (Engl). 2026 May 26. doi: 10.1097/CM9.0000000000004134. Online ahead of print.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Werkelijk)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per site
- Neoplasmata
- Ziekten van de luchtwegen
- Longziekten
- Neoplasmata van de luchtwegen
- Thoracale neoplasmata
- Longneoplasmata
- Carcinoom, bronchogeen
- Bronchiale neoplasmata
- Carcinoom, niet-kleincellige long
- Aminozuren, peptiden en eiwitten
- Organische chemicaliën
- Heterocyclische verbindingen
- Heterocyclische verbindingen, 2-ring
- Heterocyclische verbindingen, gefuseerd ring
- Coördinatiecomplexen
- Guanine
- Hypoxanthines
- Purinones
- Purines
- Glutamaten
- Aminozuren, zuur
- Aminozuren
- Aminozuren, dicarbonylisch
- Pemetrexed
- Carboplatine
- Amivantamab
Andere studie-ID-nummers
Andere studie-ID-nummers
- CR108850
- 61186372NSC3001 (Andere identificatie: Janssen Research & Development, LLC)
- 2023-506033-29-00 (Register-ID: EUCT number)
- 2023 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .